Our data suggests that intensification of upfront chemotherapy does not appear to improve treatment outcomes in CML-MBP patients however, further studies are warranted to confirm these findings involving a larger cohort. Here, MBP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.